Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-cell damage" refers to the loss of function or viability of pancreatic beta cells, which are responsible for insulin production in the islets of Langerhans. This damage can result from autoimmune attack (Type 1 diabetes), metabolic stress (Type 2 diabetes), or exposure to inflammatory cytokines, oxidative stress, or toxic metabolites. The major biochemical mechanisms include apoptosis, necroptosis, autophagy, and sometimes pyroptosis, usually driven by cytokine signaling (e.g., IL-1β, TNFα, IFNγ), oxidative stress, endoplasmic reticulum stress, mitochondrial dysfunction, and DNA damage. Loss of beta-cell mass or identity (dedifferentiation) is a hallmark of diabetes pathogenesis, leading to hyperglycemia and loss of glucose homeostasis[1][2][3][4][5][6][7]. Summary: "Beta-cell damage" is a description of a cell injury/dysfunction process, not a discrete molecular target such as a receptor or enzyme. Therefore, it does not fit as a "therapeutic target" in the typical sense and is an incorrect entry for target-based structured databases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-cell damage.